Evidence map›Paper›PMID 37485470›Full record

ArticleJournal of health economics and outcomes research2023

An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population.

Mei S Chan, Richard Holloway, Robert King, Rosie Polya, Rebecca Sloan, Jack C Kowalik, Tom Ashfield, Luke S P Moore, Thomas Porter, Jonathan Pearson-Stuttard

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of health economics and outcomes research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Val (EU) xit: do we need an international ISPOR value flower?Journal of comparative effectiveness research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mei S ChanHealth Analytics Lane Clark & Peacock LLP, London, UK.
Richard HollowayHealth Analytics Lane Clark & Peacock LLP, London, UK.
Robert KingHealth Analytics Lane Clark & Peacock LLP, London, UK.
Rosie PolyaHealth Analytics Lane Clark & Peacock LLP, London, UK.
Rebecca SloanHealth Analytics Lane Clark & Peacock LLP, London, UK.
Jack C KowalikPfizer Ltd., Tadworth, UK.
Tom AshfieldPfizer Ltd., Tadworth, UK.
Luke S P MooreChelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Thomas PorterHealth Analytics Lane Clark & Peacock LLP, London, UK.
Jonathan Pearson-StuttardHealth Analytics Lane Clark & Peacock LLP, London, UK.
Peacocks Medical Group (United Kingdom) · GBPfizer (United Kingdom) · GBChelsea and Westminster Hospital NHS Foundation Trust · GBImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antimicrobialsinsurance valuepharmacoeconomicssimulation modelingwider elements of value

Identifiers

PMID37485470
PMCPMC10359113
OpenAlexW4384661836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.